Tag: Dentistry Innovation Recognition Award

Shengping HOU | Medicine and Dentistry | Best Researcher Award

Published on by World Science Awards

Prof. Shengping HOU | Medicine and Dentistry | Best Researcher Award

Director of Beijing Institute of Ophthalmology at Beijing Institute of Ophthalmology, Beijing Tongren Eye Center, Beijing Tongren Hospital, Capital Medical University, China

Dr. Shengping Hou is a prominent figure in ophthalmology, currently serving as a Professor and Director at the Beijing Institute of Ophthalmology, Beijing Tongren Eye Center, Capital Medical University. With extensive experience in ocular immunology and stem cell biology, he has contributed significantly to advancing research in vision science. His leadership roles and numerous research grants highlight his dedication to developing innovative solutions for ocular diseases. Dr. Hou has delivered invited lectures at international conferences and is actively engaged in professional service, serving as an ad hoc reviewer for esteemed journals. His work has earned him several prestigious awards, including national recognition for his achievements in science and technology.

Professional Profile

Education

Dr. Hou earned his Ph.D. in Ocular Immunology from Sun Yat-sen University, China, in 2009, showcasing his foundation in understanding immune-related ocular diseases. He further honed his expertise as a postdoctoral fellow in Ocular Stem Cell Biology at the University of California, San Francisco, in 2016. This educational background has equipped him with cutting-edge knowledge and skills, enabling him to explore and address complex issues in ophthalmology.

Professional Experience

Dr. Hou began his career as an Associate Professor at Chongqing Medical University (2009–2015), where he played a key role in ophthalmology research at the Chongqing Key Laboratory of Ophthalmology. In 2015, he was promoted to Professor, continuing his impactful work at the same institution until 2023. Currently, Dr. Hou serves as the Director at the Beijing Institute of Ophthalmology, where he leads advanced research initiatives and oversees clinical operations.

Research Interests

Dr. Hou’s research interests focus on ocular immunology, ocular stem cell biology, and the genetic basis of ocular diseases. His work delves into understanding the molecular and genetic mechanisms underlying conditions such as VKH syndrome and Behçet’s disease, with the aim of developing innovative treatments. His commitment to translating basic research into clinical solutions highlights his dedication to improving patient outcomes in ophthalmology.

Research Skills

Dr. Hou possesses advanced expertise in genetic and molecular studies, including gene editing and analysis of copy number variants. His skills also encompass stem cell culture techniques, immunological assays, and bioinformatics tools for studying ocular diseases. Additionally, his experience in securing and leading research grants demonstrates his strategic planning and leadership abilities in scientific endeavors.

Awards and Honors

Dr. Hou has received numerous awards for his contributions to ophthalmology and scientific research. These include the First Prize for the Achievement in Science and Technology from Chongqing (2010, 2015) and the Chinese Health Ministry (2012). In 2018, he was awarded the Second Prize for Scientific and Technological Progress of China, reflecting the national recognition of his impactful work. His accolades underscore his commitment to advancing knowledge in vision science and his leadership in the field.

Conclusion

Dr. Shengping Hou is a highly accomplished researcher with significant contributions to ocular immunology and stem cell biology. His academic leadership, research funding success, and national awards make him a strong candidate for the Best Researcher Award. However, further emphasis on international collaboration, impactful publications, and translational innovations could make his candidature even more competitive. Overall, Dr. Hou’s accomplishments and leadership in ophthalmology research align well with the criteria for this prestigious award.

Publication Top Notes

  1. Ocular immune-related diseases: molecular mechanisms and therapy”
    • Authors: Wang, Y.; Gao, S.; Cao, F.; Lei, F.; Hou, S.
    • Year: 2024
  2. “m6A-methylase METTL3 promotes retinal angiogenesis through modulation of metabolic reprogramming in RPE cells”
    • Authors: Zhou, Q.; Liu, X.; Lu, H.; Yang, P.; Hou, S.
    • Year: 2024
  3. “A novel metric of autoimmune disease burden and its estimated incidence across different stages in the life cycle of women”
    • Authors: Cao, F.; Pan, H.-F.; Hou, S.
    • Year: 2024
  4. “A feedback loop driven by H3K9 lactylation and HDAC2 in endothelial cells regulates VEGF-induced angiogenesis”
    • Authors: Fan, W.; Zeng, S.; Wang, X.; Li, N.; Hou, S.
    • Year: 2024
    • Citations: 3
  5. “Transcription factor EGR2 alleviates autoimmune uveitis via activation of GDF15 to modulate the retinal microglial phenotype”
    • Authors: Li, W.; He, S.; Tan, J.; Yang, P.; Hou, S.
    • Year: 2024
    • Citations: 2
  6. “Icariin alleviates oxygen-induced retinopathy by targeting microglia hexokinase 2”
    • Authors: Li, X.; Wang, G.; Li, N.; Zhou, Q.; Hou, S.
    • Year: 2024
    • Citations: 1
  7. “Autophagy-mediated activation of the AIM2 inflammasome enhances M1 polarization of microglia and exacerbates retinal neovascularization”
    • Authors: Liu, X.; Zhou, Q.; Meng, J.; Mao, L.; Hou, S.
    • Year: 2024
    • Citations: 1
  8. “Polyvinylpyrrolidone-curcumin nanoparticles with immune regulatory and metabolism regulatory effects for the treatment of experimental autoimmune uveitis”
    • Authors: Cao, F.; Liang, K.; Tang, W.-W.; Tao, L.-M.; Wang, X.
    • Year: 2024
    • Citations: 6
  9. “Trends and cross-country inequalities in the global burden of osteoarthritis, 1990–2019: A population-based study”
    • Authors: Cao, F.; Xu, Z.; Li, X.-X.; Hou, S.; Pan, H.-F.
    • Year: 2024
    • Citations: 14
  10. “YY1 Lactylation Aggravates Autoimmune Uveitis by Enhancing Microglial Functions via Inflammatory Genes”
    • Authors: Huang, J.; Wang, X.; Li, N.; Yang, P.; Hou, S.
    • Year: 2024
    • Citations: 9

 

Laura Bauman | Dentistry | Best Researcher Award

Published on by World Science Awards

Dr. Laura Bauman | Dentistry |Best Researcher Award

Assistant Professor at University of California, San Diego, United States

Dr. Laura Elizabeth Bauman, a pediatric gastroenterologist, excels in both clinical and academic settings, making her a strong candidate for the Best Researcher Award. She completed her fellowship at Cincinnati Children’s Medical Center and has been recognized with several prestigious awards, including the Arnold W. Strauss Award and the Young Investigator Travel Award. Dr. Bauman’s leadership roles include co-directing the Fecal Microbial Transplant Program and spearheading quality improvement initiatives at Rady Children’s Pediatric IBD Center. As a peer reviewer for top journals and an active member of professional organizations, she contributes significantly to the advancement of pediatric gastroenterology. Her dedication to service is evident in her work with the Crohn’s and Colitis Foundation and her leadership in fostering inclusivity at Rady Children’s Hospital. While further expanding her grant funding and publication portfolio would strengthen her profile, Dr. Bauman’s commitment to research and patient care makes her an outstanding researcher.

Profile:

Education:

Dr. Laura Elizabeth Bauman has a robust academic background, beginning with her Bachelor of Arts in Human Biology from Stanford University in 2007. She went on to earn her Medical Doctorate from the Geisel School of Medicine at Dartmouth in 2012, where she conducted research under Dr. Kari Rosenkranz. Following medical school, Dr. Bauman completed her pediatric internship and residency at the University of Utah from 2012 to 2015, with mentorship from Drs. Mark Deneau and M. Kyle Jensen. She then pursued specialized training through a Pediatric Gastroenterology, Hepatology, and Nutrition Fellowship at Cincinnati Children’s Medical Center from 2015 to 2018, working with Dr. Lee A. Denson. This extensive education, paired with her research and clinical training in leading institutions, has equipped Dr. Bauman with the expertise needed to excel in pediatric gastroenterology, with a focus on inflammatory bowel diseases and clinical research.

Professional Experience:

Dr. Laura Elizabeth Bauman’s professional experience is marked by her dedication to pediatric gastroenterology and her leadership in both clinical and academic settings. Since completing her fellowship at Cincinnati Children’s Medical Center in 2018, she has played pivotal roles at Rady Children’s Hospital in San Diego, where she co-directs the Fecal Microbial Transplant Program and leads quality improvement initiatives for pediatric inflammatory bowel disease (IBD) patients. Dr. Bauman is a key member of the hospital’s Gastroenterology Fellowship Clinical Competency Committee and collaborates on interdisciplinary projects to enhance patient care. She also serves on national committees, such as the Crohn’s and Colitis Foundation’s Pediatric Affairs Committee, contributing to the development of educational resources and clinical guidelines. A peer reviewer for top gastroenterology journals, Dr. Bauman remains actively involved in research, mentorship, and patient care, solidifying her reputation as a leader in pediatric gastroenterology.

Research Skills:

Dr. Laura Elizabeth Bauman possesses advanced research skills honed through years of focused academic and clinical inquiry in pediatric gastroenterology. Her expertise lies in inflammatory bowel diseases (IBD), where she has led and contributed to numerous research projects aimed at improving clinical outcomes for pediatric patients. Dr. Bauman’s ability to design, implement, and oversee research is demonstrated by her leadership in quality improvement initiatives, such as developing standardized care protocols for acute severe colitis at Rady Children’s Hospital. She is skilled in interdisciplinary collaboration, as shown by her work on the Fecal Microbial Transplant Program and her involvement in the creation of the Inpatient Acute Severe Ulcerative Colitis order set. Additionally, Dr. Bauman is an experienced peer reviewer for leading journals and has been recognized with awards, including the Arnold W. Strauss Award. Her capacity to blend clinical practice with research makes her an asset to the field of pediatric gastroenterology.

Award and Recognition:
Dr. Laura Elizabeth Bauman has received numerous awards and recognitions that highlight her excellence in research, clinical practice, and education. Notably, she was awarded the prestigious Arnold W. Strauss Award, a competitive $10,000 grant aimed at advancing clinical fellows’ research, specifically for her work on refractory ulcerative colitis. She also earned the Young Investigator Travel Award from the Crohn’s and Colitis Congress, recognizing her contributions to cutting-edge research in pediatric gastroenterology. In 2013, she was honored with the Golden Apple Award from the University of Utah’s Department of Pediatrics for her exceptional teaching and mentorship of medical students. Additionally, Dr. Bauman was selected as a candidate for the National Center for Leadership in Academic Medicine in 2023, a professional development program for junior faculty at UC San Diego. These accolades reflect Dr. Bauman’s commitment to advancing her field and her outstanding capabilities as both a researcher and educator.

Conclusion:

Dr. Laura Elizabeth Bauman is an outstanding candidate for the Research for Best Researcher Award, with a deep commitment to advancing pediatric gastroenterology through research, leadership, and service. While areas such as increasing her publication profile and securing larger grants could further strengthen her candidacy, her current achievements in clinical research and professional development make her a highly competitive nominee for this award.

Publication Top Notes:

  1. Mould DR, Upton RN, Wojciechowski J.
    Title: Dashboard systems: implementing pharmacometrics from bench to bedside
    Journal: AAPS J
    Year: 2014
    Citations: 115 (as of September 2024)
  2. Eser A, Primas C, Reinisch S, et al.
    Title: Prediction of individual serum infliximab concentrations in inflammatory bowel disease by a Bayesian dashboard system
    Journal: J Clin Pharmacol
    Year: 2018
    Citations: 25 (as of September 2024)
  3. Hyams J, Walters TD, Crandall W, et al.
    Title: Safety and efficacy of maintenance infliximab therapy for moderate-to-severe Crohn’s disease in children: REACH open-label extension
    Journal: Curr Med Res Opin
    Year: 2011
    Citations: 229 (as of September 2024)
  4. Crombé V, Salleron J, Savoye G, et al.
    Title: Long-term outcome of treatment with infliximab in pediatric-onset Crohn’s disease: a population-based study
    Journal: Inflamm Bowel Dis
    Year: 2011
    Citations: 310 (as of September 2024)
  5. Wine E, Mack DR, Hyams J, et al.
    Title: Interleukin-6 is associated with steroid resistance and reflects disease activity in severe pediatric ulcerative colitis
    Journal: J Crohns Colitis
    Year: 2013
    Citations: 152 (as of September 2024)
  6. Hyams J, Crandall W, Kugathasan S, et al.; REACH Study Group
    Title: Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn’s disease in children
    Journal: Gastroenterology
    Year: 2007
    Citations: 945 (as of September 2024)
  7. Merras-Salmio L, Kolho KL.
    Title: Clinical use of infliximab trough levels and antibodies to infliximab in pediatric patients with inflammatory bowel disease
    Journal: J Pediatr Gastroenterol Nutr
    Year: 2017
    Citations: 62 (as of September 2024)
  8. Moore C, Corbett G, Moss AC.
    Title: Systematic review and meta-analysis: serum infliximab levels during maintenance therapy and outcomes in inflammatory bowel disease
    Journal: J Crohns Colitis
    Year: 2016
    Citations: 310 (as of September 2024)
  9. Frymoyer A, Hoekman DR, Piester TL, et al.
    Title: Application of population pharmacokinetic modeling for individualized infliximab dosing strategies in Crohn disease
    Journal: J Pediatr Gastroenterol Nutr
    Year: 2017
    Citations: 63 (as of September 2024)
  10. Vande Casteele N, Khanna R, Levesque BG, et al.
    Title: The relationship between infliximab concentrations, antibodies to infliximab and disease activity in Crohn’s disease
    Journal: Gut
    Year: 2015
    Citations: 725 (as of September 2024)